Previous 10 | Next 10 |
-- Cash and cash equivalents of approximately $240 million after giving effect to close -- -- Timothy C. Tyson and Andrew Oh join Syros Board of Directors -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday! Moving shares this morning are reverse stock splits, an as...
-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and ...
Syros Pharmaceuticals ( NASDAQ: SYRS ) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer. SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients wi...
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! News moving stocks this morning include clinical trial updates, earnings reports...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference. ...
Shares of Syros Pharmaceuticals ( NASDAQ: SYRS ) lost as much as 12.8% to $0.85 in Tuesday afternoon trading, after the company reported a mixed set of Q2 numbers and announced preliminary data from a dose-confirmation trial. It is worth noting that SYRS stock gained 1...
Syros Pharmaceuticals, Inc. (SYRS) Q2 2022 Earnings Conference Call August 09, 2022 08:30 AM ET Company Participants Courtney Solberg - Manager of Corporate Communications & Investor Relations Nancy Simonian - Chief Executive Officer David Roth - Chief Medica...
Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q2 GAAP EPS of -$0.54 misses by $0.13 . Revenue of $6.28M (+21.7% Y/Y) beats by $1.5M . Cash and Financial Guidance Cash, cash equivalents and marketable securities as of June 30, 2022 were $86.3 milli...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
2024-07-17 19:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...